{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T10:01:31Z","timestamp":1775728891682,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014387","name":"ACADIA Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12325-025-03484-1","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:04:26Z","timestamp":1770879866000},"page":"1536-1551","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Phase\u00a01, Randomized, Open-Label Study to Assess the Bioequivalence of Trofinetide as a Ready-to-Use Oral Solution and Constituted Powder for Oral Solution in Healthy Adults"],"prefix":"10.1007","volume":"43","author":[{"given":"Mona","family":"Darwish","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Adegbenle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Tejwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene","family":"Nunez-Disla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Youakim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjeev","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"3484_CR1","unstructured":"US Food and Drug Administration. DAYBUE (trofinetide) prescribing information. 2023. Updated August 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/217026s006,s007lbl.pdf. Accessed 18 July 2025."},{"key":"3484_CR2","unstructured":"Acadia Pharmaceuticals. DAYBUE (trofinetide) Canadian product monograph including patient medication information. Ontario, Canada 2024. Updated 11 Oct 2024. https:\/\/acadia.com\/en-ca\/pdf\/our-medicine\/health-canada-daybue-product-monograph-october-11-2024.pdf. Accessed 18 July 2025."},{"key":"3484_CR3","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","volume":"29","author":"JL Neul","year":"2023","unstructured":"Neul JL, Percy AK, Benke TA, et al. Trofinetide for the treatment of Rett syndrome: a randomized phase\u00a03 study. Nat Med. 2023;29:1468\u201375.","journal-title":"Nat Med"},{"key":"3484_CR4","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.medj.2024.05.018","volume":"5","author":"AK Percy","year":"2024","unstructured":"Percy AK, Neul JL, Benke TA, et al. Trofinetide for the treatment of Rett syndrome: results from the open-label extension LILAC study. Med. 2024;5:1178\u201389.e3.","journal-title":"Med"},{"key":"3484_CR5","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.medj.2024.06.007","volume":"5","author":"AK Percy","year":"2024","unstructured":"Percy AK, Neul JL, Benke TA, et al. Trofinetide for the treatment of Rett syndrome: long-term safety and efficacy results of the 32-month, open-label LILAC-2 study. Med. 2024;5:1275\u201381.e2.","journal-title":"Med"},{"issue":"6","key":"3484_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100608","volume":"6","author":"AK Percy","year":"2025","unstructured":"Percy AK, Ryther R, Marsh ED, et al. Results from the phase\u00a02\/3 DAFFODIL study of trofinetide in girls aged two to four years with Rett syndrome. Med. 2025;6(6):100608.","journal-title":"Med"},{"key":"3484_CR7","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/ana.22124","volume":"68","author":"JL Neul","year":"2010","unstructured":"Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 2010;68:944\u201350.","journal-title":"Ann Neurol"},{"key":"3484_CR8","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1177\/0003489417723033","volume":"126","author":"C Mezzedimi","year":"2017","unstructured":"Mezzedimi C, Livi W, De Felice C, Cocca S. Dysphagia in Rett syndrome: a descriptive study. Ann Otol Rhinol Laryngol. 2017;126:640\u20135.","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"3484_CR9","unstructured":"US Food and Drug Administration, Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research. M9 biopharmaceutics classification system-based biowaivers: guidance for industry [docket #: FDA-2018-D-3614]. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2021. Updated May\u00a02021. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/m9-biopharmaceutics-classification-system-based-biowaivers. Accessed 26 Aug 2025."},{"key":"3484_CR10","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40261-022-01156-4","volume":"42","author":"M Darwish","year":"2022","unstructured":"Darwish M, Youakim JM, Harlick J, DeKarske D, Stankovic S. A phase\u00a01, open-label study to evaluate the effects of food and evening dosing on the pharmacokinetics of oral trofinetide in healthy adult subjects. Clin Drug Investig. 2022;42:513\u201324.","journal-title":"Clin Drug Investig"},{"key":"3484_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40261-023-01322-2","volume":"44","author":"M Darwish","year":"2024","unstructured":"Darwish M, Nunez R, Youakim JM, Robertson P Jr. Characterization of the pharmacokinetics and mass balance of a single oral dose of trofinetide in healthy male subjects. Clin Drug Investig. 2024;44:21\u201333.","journal-title":"Clin Drug Investig"},{"key":"3484_CR12","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. Guidance for industry: Statistical approaches to establishing bioequivalence. 2001. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/statistical-approaches-establishing-bioequivalence. 29 Sept 2025."},{"key":"3484_CR13","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1016\/j.ejps.2017.05.032","volume":"109S","author":"SP Oosterholt","year":"2017","unstructured":"Oosterholt SP, Horrigan J, Jones N, Glass L, Della Pasqua O. Population pharmacokinetics of NNZ-2566 in healthy subjects. Eur J Pharm Sci. 2017;109S:S98\u2013107.","journal-title":"Eur J Pharm Sci"},{"key":"3484_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s13318-024-00924-1","volume":"50","author":"M Darwish","year":"2025","unstructured":"Darwish M, Marbury TC, Nunez R, et al. Physiologically-based pharmacokinetic modeling of trofinetide in moderate renal impairment for phase\u00a01 clinical study dose selection with model validation. Eur J Drug Metab Pharmacokinet. 2025;50:23\u201338.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"3484_CR15","doi-asserted-by":"publisher","first-page":"2449346","DOI":"10.1080\/23995270.2024.2449346","volume":"5","author":"M Darwish","year":"2025","unstructured":"Darwish M, Youakim JM, Mason JW, Stanworth S, Sanabria C. Assessing the effects of trofinetide on QTc interval, safety and tolerability, and pharmacokinetics in healthy adults. Future Rare Dis. 2025;5:2449346.","journal-title":"Future Rare Dis"},{"key":"3484_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1651-2227.1985.tb10993.x","volume":"74","author":"B Hagberg","year":"1985","unstructured":"Hagberg B. Rett\u2019s syndrome: prevalence and impact on progressive severe mental retardation in girls. Acta Paediatr Scand. 1985;74:405\u20138.","journal-title":"Acta Paediatr Scand"},{"key":"3484_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","volume":"48","author":"OP Soldin","year":"2009","unstructured":"Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48:143\u201357.","journal-title":"Clin Pharmacokinet"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03484-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03484-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03484-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:13:55Z","timestamp":1775726035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03484-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["3484"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03484-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mona Darwish, Amy Yamamoto, Yvonne Adegbenle, Ravi Tejwani, Yonghua Chen, Rene Nunez-Disla, James M. Youakim, and Sanjeev Pathak are employees and stakeholders of Acadia Pharmaceuticals Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All requisite study-related material, including the protocol, was reviewed by an institutional review board\/ethics committee (Advarra #Pro00079521, IRB approval May\u00a017, 2024). All subjects provided written informed consent for participation in the study. The study was performed in full conformity with the current Declaration of Helsinki, the International Council for Harmonisation Guideline for Good Clinical Practice, and all other applicable regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\/Ethical Approval"}}]}}